Welcome to our dedicated page for brks news (Ticker: brks), a resource for investors and traders seeking the latest updates and insights on brks stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect brks's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of brks's position in the market.
Brooks Automation (Nasdaq: BRKS) announced its upcoming participation in the 12th Annual Virtual CEO Investor Summit on December 16, 2020. This event, which is invitation-only for accredited investors and research analysts, will feature a round-robin format with up to six 40-minute meetings dedicated to discussing the company's business and opportunities. The company specializes in life science sample management and semiconductor manufacturing solutions. Brooks is headquartered in Chelmsford, MA, and serves clients globally.
Brooks Automation (Nasdaq: BRKS) has acquired Trans-Hit Biomarkers Inc. (THB), enhancing its life sciences business with THB's biospecimen procurement services. THB specializes in managing biospecimens for biopharma and diagnostics across various fields, including oncology and infectious diseases. The acquisition is expected to provide immediate modest earnings accretion. Dr. Pascal Puchois will continue to lead THB under Brooks. The exact terms of the deal remain undisclosed, but the integration is anticipated to add growth potential to Brooks Life Sciences.
Brooks Automation (Nasdaq: BRKS) announced its participation in two upcoming virtual investor conferences. The Credit Suisse 24th Annual Virtual Technology Conference is scheduled for December 1, 2020, at 4:10 p.m. ET, while the Wells Fargo Virtual TMT Summit 2020 will follow on December 2, 2020, at 12:40 p.m. ET. Investors can access the live webcasts through the company’s Investor Relations page. A replay will be available after the events. Brooks Automation is a leader in life science sample management and semiconductor manufacturing solutions, operating globally from Chelmsford, MA.
Brooks Automation (Nasdaq: BRKS) will participate in the Stephens Annual Investment Conference 2020 on November 19, 2020. The event will include a 45-minute webcast starting at 9:00 a.m. ET, accessible via Brooks' investor relations website. A replay will be available post-event. Brooks, headquartered in Chelmsford, Massachusetts, is a leading provider of life science sample management and semiconductor manufacturing solutions, serving top pharmaceutical and biotech sectors worldwide.
Brooks Automation reported strong financial results for Q4 and FY 2020, with revenues of $246 million and $897 million, reflecting year-over-year increases of 24% and 15%, respectively. Diluted EPS from continuing operations surged to $0.39, up from $0.07 in Q4 2019. The Semiconductor Solutions and Life Sciences segments demonstrated robust growth, with increases of 31% and 15% in Q4. Non-GAAP diluted EPS also rose by 100% to $0.47. The company ended Q4 with $306 million in cash and announced a dividend of $0.10 per share. For Q1 FY 2021, revenue guidance is set between $237 million and $251 million.
Brooks Automation (Nasdaq: BRKS) will report its fiscal 2020 fourth quarter and year-end earnings on November 10, 2020, after market close. A conference call will be held the same day at 4:30 p.m. ET to discuss the financial results. Investors and analysts can access the live webcast through the Brooks website. The company specializes in life science sample management and semiconductor manufacturing solutions, supporting key sectors such as drug development and genomic analysis. Brooks operates globally, including in North America, Europe, and Asia.
Brooks Automation (Nasdaq: BRKS) announced that Dr. Amy Liao, president of Brooks Life Science Services, has received the prestigious Wallace A. Coulter award for healthcare innovation on October 16, 2020. This award honors individuals for their lifetime contributions to patient healthcare. Dr. Liao, recognized for her over 20 years in genomics, will address the 2020 Biomedical Engineering Society's virtual meeting. Under her leadership, Brooks' GENEWIZ division has become a key player in genomic services, enhancing the company’s reputation and innovation in healthcare.
Brooks Automation (Nasdaq: BRKS) will participate in Citi's 2020 Global Technology Virtual Conference on September 9, 2020. The event includes a 45-minute live webcast starting at 9:50 a.m. ET. Investors can access the webcast via Brooks' investor relations website, with a replay available post-event. Brooks is a leader in life science sample management and semiconductor manufacturing solutions, serving top pharmaceutical and semiconductor companies globally.
Brooks Automation (Nasdaq: BRKS) announced today its participation in the Needham Virtual SemiCap and Electronic Design Automation Conference on August 13, 2020, at 9:30 a.m. ET. The event will feature a 40-minute session, which will be webcast live. Brooks Automation is a leader in life science sample management and semiconductor manufacturing solutions globally, serving pharmaceutical, biotech, and semiconductor industries. The company is headquartered in Chelmsford, MA, with operations across North America, Europe, and Asia.
Brooks Automation reported Q3 2020 financial results, achieving $220 million in revenue, an 8% increase year-over-year. The Semiconductor Solutions segment generated $127 million in revenue, up 9%, while Life Sciences saw $93 million, a 6% growth. Diluted EPS from continuing operations rose to $0.19, a significant increase of 49% compared to Q3 2019. Cash flow from operations was $26 million, with a strong cash position of $263 million. The company projects Q4 revenue between $229 million and $241 million with EPS guidance of $0.19 to $0.27.
